Exchange: NASDAQ·Updated 07:53 PM EDT
News
all
press releases
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Zacks
More News
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
Zacks
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Zacks
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...
Business Wire
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
Zacks
Why Biogen Stock Topped the Market Today
Key PointsIt handily beat analyst estimates on both the top and bottom lines...
Nasdaq News: Markets
Q2 Earnings Season in Full Swing
Q2 Earnings Season in Full Swing
Zacks
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Zacks
Investors Await Fed Decision Today
A quarter-points rate hike has been bandied about as a possibility today.
Zacks
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks

Advertisement|Remove ads.